Global Harmonization
Efforts beyond ICH
Justina A. Molzon, MS Pharm, JD
Associate Director for International Programs
Center for Drug Evaluation and Research
US Food and Drug Administration
ICH Steering Committee Member
The views expressed in this presentation are those of the author and do not necessarily represent the views of the U.S. Food and Drug Administration 1
Harmonization in Drug Regulation
Process of integrating national standards withProcess of integrating national standards with international standards to be universally acceptableinternational standards to be universally acceptable to participating countries toto participating countries to facilitate efficient globalfacilitate efficient global drug development and local registrationdrug development and local registration
✦Technical and science requirements
✦Format and content of dossiers
✦Assessment and review practices
2
3
ICH INTERNATIONAL CONFERENCE ON
HARMONIS/ZATION of
Technical Requirements
for the Registration of
Pharmaceuticals for Human Use
http://www.ich.org Hosted by ICH Secretariat
IFPMA-Geneva, Switzerland 3
4
A Unique Approach • ICH was created in 1990 • Agreement between the EU, Japan and the USA
to harmonize different regional requirements forregistration of pharmaceutical drug products – Canada, EFTA and WHO participate in ICH as
observers
• Unique because joint effort by regulators and
associated pharmaceutical industry trade
associations (includes Generics and OTC)
• Pharmaceutical industry aware of areas of disharmony in regulatory submission requirements
4
5
ICH Harmonized Guidelines
• Efficacy - 16 topic headings/20 guidelines • Safety - 9 topic headings/15 guidelines • Quality - 10 topic headings/39 guidelines • Multidisciplinary (Regulatory Communications)
– Medical Dictionary - MedDRA – Electronic Standards - ESTRI, E2B, eCTD
• In 1996 ICH industry representatives proposed assembling the information generated by these harmonized guidancesin the same order
• Goal was to decrease the amount of time and staff needed to assemble and disassemble documents for submission to ICH regions 5
66
Concerns • Regulators realized the amount of time and
energy needed to rearrange paper from one ICH region submission format to another
• Conversion caused a delay in submitting an application to that ICH region
• Resulted in delayed access to new innovative medicines for patients in that region
7
8
ICH CTDICH CTD
1.0 Regional Administrative I
Module 1
Module 3 Module 4 Module 5
2.1
2.2
2.3 2.4 2.5
2.6 2.7
1.0
Quality 3.0
Nonclinical Study Reports
4.0
Clinical Study Reports
5.0
1.1 ToC of Module 1 or overaincluding Module 1
2.1 ToC of the 2.2 Introduction
Module 2 2.3 Quality Ove2.4 Nonclinical 2.5 Clinical Ove2.6 Nonclinical
2.7 Clinical S
Source: ICH Impleme
nformation
8
ll ToC,
CTD (Mod 2,3,4,5)
rall Summary
Overview
rview
Summary
ummary
ntation Coordination Group
9
Benefits of the CTD--FDA Perspective
• More reviewable applications More logical order of presentation Follows development scheme
• More predictable format • More consistent reviews • Easier analysis across applications • Easier exchange of information • Facilitates electronic submissions
9
10
eCTD Format and the Review Process
ICH Guidelines
CTD
eReview
Easier to Develop Standardized Reviewer eTemplates
Promotes eSubmission and eReview tools
10
ICH Global Influence
11
ICH Global Cooperation Group
• Created in 1999 to address increasing interest by non-ICH parties in ICH guidelinesand operations
• Initial focus on information-sharing • Soon became clear that more active
engagement was necessary to respond toincreasing interest in ICH and ICHguidelines
• Invited participation of regional 12pharmaceutical harmonization initiatives
•
•
AP– A
AS– A
GC– PA– P
SA– S
•
•
•
Regional Harmonization Initiatives
EC sia-Pacific Economic Cooperation
EAN ssociation of the Southeast Asian Nations
C Gulf Cooperation Council NDRH an American Network for Drug Regulatory
Harmonization DC
outhern African Development Community 13
Expanded GCG ICH Meetings June 8-12, 2008
• Participation of individual countries for first time
• Distinct and complementary to participation of official RHI representatives
• Expansion of GCG to specific countries based on considerations such as: • Source of APIs, medicinal products and
clinical data for ICH regions • Use or intended use of ICH guidelines
14
Expanded GCG
Invitations Extended to Individual Drug
Regulatory Authorities
• Australia • India • Brazil • Korea • China • Russia • Chinese Taipei • Singapore
15
Regulators Forum • Met for the first time prior to ICH meetings
in Portland, June 9, 2008 • Created to promote discussion and sharing
of best practices among regulatory authorities on issues related to the implementation of ICH guidelines andimpact on regulatory systems
• The Regulators’ Forum will complement activities and objectives of GCG
16
ICH Week Steering Committee
GCG meeting expanded
Industry meeting (ICG)
Regulators meeting
ThursWedTueMonSun
Regulators Forum
ICH Working Groups
Complementary 17
Core GXP Information
GMP, GCP PCV
GRP, CTD
MHLW EMEA
HC
Swiss
FDA
18
Develop > DisseminateDisseminate > ImplementImplement
Conclusion • The geographical face of international drug
development and trade is rapidly changing
• Interest and use of ICH guidelines by non-ICH countries reflects this change
• The influence of ICH on drug development and the submission process will most likely spread across both ICH and non-ICH regions
19
Thank you for yourThank you for your
attentionattention
Commissioned Corps of the United States Public Health Service Protecting,
promoting, and advancing the health and safety of the Nation
20